TFRC and synovial sarcoma: Catalpol, sirolimus, and abatacept (CTLA-4-Ig fusion protein) therapy could reduce cTfh cells and upregulate cTfr cells and restore Tfh/Tfr ratio, which led to attenuate Tfh cell-dependent B-cell hyperactivity of SS (78, 130, 131).